GlobeNewswire: ILiAD Biotechnologies, LLC Contains the last 10 of 3 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:36:45ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/05/15/1502776/0/en/NIAID-Sponsors-ILiAD-Biotechnologies-BPZE1-Pertussis-Vaccine-Phase-2a-Clinical-Study-at-Vanderbilt-University.html?f=22&fvtc=4&fvtv=28297NIAID Sponsors ILiAD Biotechnologies BPZE1 Pertussis Vaccine Phase 2a Clinical Study at Vanderbilt University2018-05-15T14:00:00Z<![CDATA[WESTON, Fla. and NASHVILLE, Tenn., May 15, 2018 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD) and Vanderbilt University Medical Center today announced filing of an Investigational New Drug (IND) application by the National Institute for Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) to study the next generation pertussis vaccine BPZE1 at the Vanderbilt Vaccine Research Program.]]>https://www.globenewswire.com/news-release/2017/07/05/1038983/0/en/ILiAD-Biotechnologies-BPZE1-Pertussis-Vaccine-Reaches-Key-Milestones-Including-Positive-Phase-1b-Clinical-Study-Data.html?f=22&fvtc=4&fvtv=28297ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data2017-07-05T13:00:00Z<![CDATA[NEW YORK, July 05, 2017 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, today announced promising results from its Phase 1b pertussis vaccine clinical trial conducted in Stockholm, Sweden, as well as publication of a landmark non-human primate study.]]>https://www.globenewswire.com/news-release/2016/02/19/812416/0/en/Phase-1b-Clinical-Trial-of-BPZE1-Pertussis-Vaccine-Completes-Enrollment-of-Randomized-Study-Groups.html?f=22&fvtc=4&fvtv=28297Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups2016-02-19T14:55:12Z<![CDATA[NEW YORK, Feb. 19, 2016 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, announced today that enrollment has been completed for three randomized groups of study subjects in a Phase 1b vaccine clinical trial being conducted in Stockholm, Sweden. ]]>